Open, randomized, controlled, multicenter phase II study comparing 5-FU/FA plus oxaliplatin FOLFOX-4 plus cetuximab versus 5-FU/FA plus oxaliplatin as first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer.

• Conditions: first-line treatment for epidermal growth factor receptor-expressing metastatic colorectal cancer.; MedDRA version: 6.1Level: PTClassification code 10061451

• Registration Number: EUCTR2005-000970-37-IT
• Lead Sponsor: MERCK S.P.A.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-03-20
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ;Secondary Objective: ;Primary end point(s):